Rebate contracts: reasons not to substitute

21. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA) - 21st Annual Meeting of the German Drug Utilisation Research Group (GAA), 20.11. - 21.11.2014, Bonn.

vandusen.dimdi.de/static/de/meetings/gaa2014/14gaa28.shtml

Conflicts of interests: none declared.

Impact of rebate contract legislation on generic substitution of valproate – a retrospective study of ambulatory drug dispensing in the DAPI database

Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib

Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database

Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.

Comparison of different ways of calculation (DDD vs. SPC) to determine persistence and compliance with beta blockers in the DAPI database.

Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.

Association between generic substitution of valproate and therapeutic modification of antiepileptic therapy – a cohort study with time-dependent exposure utilizing the DAPI ambulatory drug claims data